ArticleActa biomaterialia2022
Tissue-adhesive hydrogel for multimodal drug release to immune cells in skin.
Article in Acta biomaterialia, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 18 citations in OpenAlex.
- Targeting the neuro-immune-skin axis: Advanced functional biomaterials for intelligent wound management and regeneration.Materials today. Bio · 2026Review
- Revisiting Colloid Theory for Biomedicine: Reconciling Simple Models in Complex Environments.ACS nano medicine · 2026Article
- Konjac Glucomannan as a Gel-Forming Biopolymer for Transdermal Drug Delivery: Properties, Formulation Strategies, and Translational Challenges.Drug design, development and therapy · 2026Review
- Ionic Liquid-Mediated Delivery of Ruxolitinib to Skin Using an Adhesive Topical Hydrogel System.Advanced healthcare materials · 2025Article
- Soft Extrudable Dendritic Particles with Nanostructured Tendrils for Local Adhesion and Drug Release to Bladder Cancers.Advanced materials (Deerfield Beach, Fla.) · 2025Article
- Hydrogel applications: a promising frontier in pneumonia therapy.Frontiers in bioengineering and biotechnology · 2025Review
- Magnetic Cellular Backpacks for Spatial Targeting, Imaging, and Immunotherapy.ACS applied bio materials · 2024Review
- Advancing immunotherapy using biomaterials to control tissue, cellular, and molecular level immune signaling in skin.Advanced drug delivery reviews · 2024Review
- Recent Advances in the Degradability and Applications of Tissue Adhesives Based on Biodegradable Polymers.International journal of molecular sciences · 2024Review
- Review
- Bubble-Based Microrobots with Rapid Circular Motions for Epithelial Pinning and Drug Delivery.Small (Weinheim an der Bergstrasse, Germany) · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Both innate and adaptive immune systems play a crucial role in the pathology of skin diseases. To control these cells, there is a need for transdermal drug delivery systems that can target multiple cell populations at independently tunable rates. Herein, we describe a tissue-adhesive hydrogel system that contains particles capable of regulating the release of small molecule drugs at defined rates. Resiquimod (a macrophage-targeting drug) and palbociclib (a T cell-targeting drug) are encapsulated within two types of silicone particles embedded within the hydrogel. We demonstrate that drug release is mediated by the crosslink density of the particles, which is decoupled from the bulk properties of the hydrogel. We show that this system can be used to sustainably polarize macrophages toward an anti-tumor phenotype in vitro and ex vivo, and that the hydrogels can remain attached to skin explants for several days without generating toxicity. The hydrogel system is compatible with standard dermatological procedures and allows transdermal passage of drugs. The multimodal, tunable nature of this system has implications in treating a variety of skin disorders, managing infections, and delivering vaccines. STATEMENT OF SIGNIFICANCE: We describe a tissue-adhesive hydrogel that can regulate the release of drugs in a manner that is decoupled from its bulk properties. The mechanism of drug release is mediated by embedded microparticles with well-defined crosslink densities. The significance of this system is that, by encapsulating different drugs into the particles, it is possible to achieve multimodal drug release. We demonstrate this capability by releasing two immunomodulatory drugs at disparate rates. A drug that targets innate immune cells is released quickly, and a drug that targets adaptive immune cells is released slowly. This programmable system offers a direct means by which cellular responses can be enhanced through independent targeting for a variety of transdermal applications, including cancer treatment and vaccine delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.